Retatrutide, known in the literature by its development code LY3437943, is an investigational synthetic peptide that acts at three receptors at once. It is supplied here strictly as a research material for in-vitro laboratory work.
Retatrutide is a single-molecule agonist at three distinct receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon. Earlier molecules in this class targeted one receptor (such as semaglutide at GLP-1) or two (tirzepatide at GLP-1 and GIP). Retatrutide is described as a triple agonist, and is one of the most studied examples of that approach.
It originates from the Eli Lilly research programme and has been evaluated in company-sponsored clinical trials. Phase 2 results in obesity and in type 2 diabetes were published in the New England Journal of Medicine in 2023. The phase 3 programme, conducted under the TRIUMPH name, has since reported results from several of its trials, announced by the sponsor from late 2025 onwards.
This is an important distinction for anyone assessing the evidence: retatrutide has genuine human clinical data behind it, which separates it from most research peptides whose evidence base is entirely preclinical. What it does not have is regulatory approval.
GLP-1 is an incretin hormone released from intestinal L-cells after eating. Agonism at its receptor is studied in relation to glucose-dependent insulin secretion, gastric emptying and central appetite signalling.
GIP is the other principal incretin, released from K-cells in the upper small intestine. Its role is studied in insulin secretion and in adipose tissue handling of nutrients. Whether GIP receptor agonism or antagonism is preferable remains an open question in the literature.
Glucagon receptor activity is studied in relation to hepatic glucose output and energy expenditure. Adding it to an incretin agonist is the feature that distinguishes triple agonists from dual agonists, and it is the component under the most active investigation.
Batch documentation for Retatrutide is available on request where we hold it. We do not publish a public batch database, and no purity, identity, sterility or manufacturing claim is stated anywhere on this site unless documentation for that exact batch supports it. To ask what is held for a particular lot, contact us.
These are starting points for your own reading, not endorsements of any conclusion.
No. It holds no marketing authorisation from the MHRA, EMA or FDA and remains investigational. Several of its phase 3 trials have now reported and the sponsor has said it intends to file for approval, but no regulator has granted one.
It means a single molecule activates three receptors — GLP-1, GIP and glucagon. Single agonists act at one and dual agonists at two. The third target is what distinguishes retatrutide from earlier molecules in the class.
Yes, and more than for almost any other compound discussed as a research peptide. Phase 2 results in obesity and type 2 diabetes were published in the New England Journal of Medicine in 2023, and several phase 3 trials have since reported. This is unusual: most research peptides have only preclinical data.
No. We do not provide dosing schedules, administration guidance or reconstitution instructions for any product, and we will decline requests for them. Material is supplied for laboratory research only.
Batch documentation is available on request where it is held. We do not state results for certificates we do not hold.
This product is supplied strictly for in-vitro laboratory research. It is not a medicine, is not licensed by the MHRA, and is not for human or veterinary consumption or administration. We do not supply dosing, reconstitution or administration guidance, and nothing on this page is a therapeutic claim.